Paclitaxel Protein-bound 100mg Injection Exporter from India to USA – Ernest Oncology

Comprehensive Guide to Nab-paclieva 100mg Injection: Global Export & Distribution by Ernest Oncology

At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Nab-paclieva 100mg Injection (Paclitaxel Protein-Bound Particles for Injectable Suspension) to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

.

1. Product Information: Nab-paclieva 100mg Injection

Nab-paclieva 100mg Injection is an anti-cancer (chemotherapy) medication in which paclitaxel is bound to human albumin nanoparticles. This nanoparticle formulation improves drug delivery to tumor cells and eliminates the need for solvents that can cause allergic reactions.

Key Product Details

• Composition: Paclitaxel (protein-bound particles) 100 mg.

• Therapeutic Class: Anti-neoplastic agent / Antimicrotubular agent.

• Formulation Type: Nanoparticle albumin-bound (nab-paclitaxel).

• Storage Temperature: Store at 20°C to 25°C.

2. Mechanism of Action

Nab-paclieva functions through targeted nanoparticle delivery:

• Microtubule Stabilization: Paclitaxel binds to tubulin, promoting the assembly of microtubules while preventing their breakdown, which locks the cell in the G2/M phase.

• Tumor Targeting: The albumin-bound nanoparticles utilize the body's natural albumin pathways to accumulate in tumor tissues at higher concentrations.

• Apoptosis: The resulting mitotic arrest triggers apoptosis (programmed cell death) and reduces systemic toxicity compared to solvent-based formulations.

3. Therapeutic Indications and Uses

Nab-paclieva 100mg Injection is indicated for:

• Metastatic Breast Cancer: Used when initial combination chemotherapy has failed or relapse has occurred within six months of adjuvant therapy.

• Non-Small Cell Lung Cancer (NSCLC): Administered in combination with carboplatin as a first-line treatment for patients who are not candidates for curative surgery or radiation.

• Pancreatic Adenocarcinoma: Used in combination with gemcitabine as a first-line treatment for patients with metastatic pancreatic cancer.

• AIDS-Related Kaposi's Sarcoma: Used when other therapies have failed.

4. Administration and Safety Warnings

Administration

• Route of Administration: Intravenous (IV) infusion over a specified period (e.g., 30 minutes) under the supervision of a qualified oncologist.

• Preparation: Prepared as an injectable suspension after reconstitution, ensuring strict aseptic techniques.

Side Effects & Precautions

• Common Side Effects: Nausea, vomiting, peripheral neuropathy (numbness or tingling in hands and feet), fatigue, hair loss (alopecia), and joint/muscle pain.

• Serious Risks: Severe hypersensitivity reactions and bone marrow suppression leading to neutropenia.

• Contraindications: Pregnancy, lactation, and patients with baseline low neutrophil counts.